TY  - JOUR
AU  - Živanović, Miloš Z.
AU  - Vukanac, Ivana
AU  - Samac, Jelena
AU  - Antić, Vojislav
AU  - Jeremić, Marija
AU  - Janković, Drina
AU  - Kandić, Aleksandar
AU  - Vargas, Clarita Saldarriaga
AU  - Struelens, Lara
AU  - Ciraj-Bjelac, Olivera
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10016
AB  - The purpose of this work is to assess accuracy and compare the performance of radionuclide calibrators (RNCs) used in nuclear medicine departments in Serbia. Testing of the RNCs included verification of measurement accuracy, as well as analysis of routinely used quality control protocols, by using the certified radioactivity standards (57Co, 137Cs). RNCs performances were assessed with 99mTc through comparison of reference value for radionuclide activity and RNC measurements. Results of the intercomparison revealed that RNCs, 15 in total, are accurate within 10% in vial geometry and within 15% in syringe geometry. Most of them showed similar performance. The results revealed that container geometry is an important influencing parameter in the accuracy of activity measurement. Obtained results indicate a need for regular calibration and implementation of Quality Control program in order to achieve and maintain the accuracy of activity measurements in nuclear medicine.
T2  - Applied Radiation and Isotopes
T1  - Intercomparison and performance assessment of radionuclide calibrators used in nuclear medicine departments in Serbia
VL  - 179
SP  - 110013
DO  - 10.1016/j.apradiso.2021.110013
ER  - 

@article{
author = "Živanović, Miloš Z. and Vukanac, Ivana and Samac, Jelena and Antić, Vojislav and Jeremić, Marija and Janković, Drina and Kandić, Aleksandar and Vargas, Clarita Saldarriaga and Struelens, Lara and Ciraj-Bjelac, Olivera",
year = "2022",
abstract = "The purpose of this work is to assess accuracy and compare the performance of radionuclide calibrators (RNCs) used in nuclear medicine departments in Serbia. Testing of the RNCs included verification of measurement accuracy, as well as analysis of routinely used quality control protocols, by using the certified radioactivity standards (57Co, 137Cs). RNCs performances were assessed with 99mTc through comparison of reference value for radionuclide activity and RNC measurements. Results of the intercomparison revealed that RNCs, 15 in total, are accurate within 10% in vial geometry and within 15% in syringe geometry. Most of them showed similar performance. The results revealed that container geometry is an important influencing parameter in the accuracy of activity measurement. Obtained results indicate a need for regular calibration and implementation of Quality Control program in order to achieve and maintain the accuracy of activity measurements in nuclear medicine.",
journal = "Applied Radiation and Isotopes",
title = "Intercomparison and performance assessment of radionuclide calibrators used in nuclear medicine departments in Serbia",
volume = "179",
pages = "110013",
doi = "10.1016/j.apradiso.2021.110013"
}

Živanović, M. Z., Vukanac, I., Samac, J., Antić, V., Jeremić, M., Janković, D., Kandić, A., Vargas, C. S., Struelens, L.,& Ciraj-Bjelac, O.. (2022). Intercomparison and performance assessment of radionuclide calibrators used in nuclear medicine departments in Serbia. in Applied Radiation and Isotopes, 179, 110013.
https://doi.org/10.1016/j.apradiso.2021.110013

Živanović MZ, Vukanac I, Samac J, Antić V, Jeremić M, Janković D, Kandić A, Vargas CS, Struelens L, Ciraj-Bjelac O. Intercomparison and performance assessment of radionuclide calibrators used in nuclear medicine departments in Serbia. in Applied Radiation and Isotopes. 2022;179:110013.
doi:10.1016/j.apradiso.2021.110013 .

Živanović, Miloš Z., Vukanac, Ivana, Samac, Jelena, Antić, Vojislav, Jeremić, Marija, Janković, Drina, Kandić, Aleksandar, Vargas, Clarita Saldarriaga, Struelens, Lara, Ciraj-Bjelac, Olivera, "Intercomparison and performance assessment of radionuclide calibrators used in nuclear medicine departments in Serbia" in Applied Radiation and Isotopes, 179 (2022):110013,
https://doi.org/10.1016/j.apradiso.2021.110013 . .

TY  - JOUR
AU  - Isaković, Anđelka
AU  - Čolović, Mirjana B.
AU  - Ma, Tian
AU  - Ma, Xiang
AU  - Jeremić, Marija
AU  - Gerić, Marko
AU  - Gajski, Goran
AU  - Misirlić-Denčić, Sonja
AU  - Kortz, Ulrich
AU  - Krstić, Danijela Z.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9952
AB  - Polyoxo-noble-metalates (PONMs), a class of molecular noble metal-oxo nanoclusters that combine features of both polyoxometalates and noble metals, are a promising platform for the development of next-generation antitumor metallodrugs. This study aimed to evaluate the antitumor potential against human neuroblastoma cells (SH-SY5Y), as well as toxicity towards healthy human peripheral blood cells (HPBCs), of five polyoxopalladates(II): (Na8[Pd13As8O34(OH)6]·42H2O (Pd13), Na4[SrPd12O6(OH)3(PhAsO3)6(OAc)3]·2NaOAc·32H2O (SrPd12), Na6[Pd13(AsPh)8O32]·23H2O (Pd13L), Na12[SnO8Pd12(PO4)8]·43H2O (SnPd12), and Na12[PbO8Pd12(PO4)8]·38H2O (PbPd12)), as the largest subset of PONMs. A pure inorganic, Pd13, was found as the most potent and selective antineuroblastoma agent with IC50 values (µM) of 7.2 ± 2.2 and 4.4 ± 1.2 for 24 and 48 h treatment, respectively, even lower than cisplatin (28.4 ± 7.4 and 11.6 ± 0.8). The obtained IC50 values (µM) for 24/48 h treatment with SrPd12 and Pd13L were 75.8 ± 6.7/76.7 ± 22.9 and 63.8 ± 3.6/21.4 ± 10.8, respectively, whereas SnPd12 and PbPd12 did not remarkably affect the SH-SY5Y viability (IC50 > > 100 µM). Pd13 caused depolarisation of inner mitochondrial membrane prior to superoxide ion hyperproduction, followed by caspase activation, DNA fragmentation and cell cycle arrest, all hallmarks of apoptotic cell death, and accompanied by an increase in acidic vesicles content, suggestive of autophagy induction. Importantly, Pd13 demonstrated the antitumor effect at concentrations not cytogenotoxic for normal HPBCs. On the contrary, SrPd12 and Pd13L at concentrations ≥ 1/3 IC50 (24 h) decreased HPBC viability and increased % tail DNA up to 42% and 3.05 times, respectively, related to control. SnPd12 and PbPd12, previously confirmed promising antileukemic agents, did not exhibit cytogenotoxicity to HPBCs, and thus could be regarded as tumor cell specific and selective drug candidates.
T2  - JBIC Journal of Biological Inorganic Chemistry
T1  - Selected polyoxopalladates as promising and selective antitumor drug candidates
VL  - 26
IS  - 8
SP  - 957
EP  - 971
DO  - 10.1007/s00775-021-01905-4
ER  - 

@article{
author = "Isaković, Anđelka and Čolović, Mirjana B. and Ma, Tian and Ma, Xiang and Jeremić, Marija and Gerić, Marko and Gajski, Goran and Misirlić-Denčić, Sonja and Kortz, Ulrich and Krstić, Danijela Z.",
year = "2021",
abstract = "Polyoxo-noble-metalates (PONMs), a class of molecular noble metal-oxo nanoclusters that combine features of both polyoxometalates and noble metals, are a promising platform for the development of next-generation antitumor metallodrugs. This study aimed to evaluate the antitumor potential against human neuroblastoma cells (SH-SY5Y), as well as toxicity towards healthy human peripheral blood cells (HPBCs), of five polyoxopalladates(II): (Na8[Pd13As8O34(OH)6]·42H2O (Pd13), Na4[SrPd12O6(OH)3(PhAsO3)6(OAc)3]·2NaOAc·32H2O (SrPd12), Na6[Pd13(AsPh)8O32]·23H2O (Pd13L), Na12[SnO8Pd12(PO4)8]·43H2O (SnPd12), and Na12[PbO8Pd12(PO4)8]·38H2O (PbPd12)), as the largest subset of PONMs. A pure inorganic, Pd13, was found as the most potent and selective antineuroblastoma agent with IC50 values (µM) of 7.2 ± 2.2 and 4.4 ± 1.2 for 24 and 48 h treatment, respectively, even lower than cisplatin (28.4 ± 7.4 and 11.6 ± 0.8). The obtained IC50 values (µM) for 24/48 h treatment with SrPd12 and Pd13L were 75.8 ± 6.7/76.7 ± 22.9 and 63.8 ± 3.6/21.4 ± 10.8, respectively, whereas SnPd12 and PbPd12 did not remarkably affect the SH-SY5Y viability (IC50 > > 100 µM). Pd13 caused depolarisation of inner mitochondrial membrane prior to superoxide ion hyperproduction, followed by caspase activation, DNA fragmentation and cell cycle arrest, all hallmarks of apoptotic cell death, and accompanied by an increase in acidic vesicles content, suggestive of autophagy induction. Importantly, Pd13 demonstrated the antitumor effect at concentrations not cytogenotoxic for normal HPBCs. On the contrary, SrPd12 and Pd13L at concentrations ≥ 1/3 IC50 (24 h) decreased HPBC viability and increased % tail DNA up to 42% and 3.05 times, respectively, related to control. SnPd12 and PbPd12, previously confirmed promising antileukemic agents, did not exhibit cytogenotoxicity to HPBCs, and thus could be regarded as tumor cell specific and selective drug candidates.",
journal = "JBIC Journal of Biological Inorganic Chemistry",
title = "Selected polyoxopalladates as promising and selective antitumor drug candidates",
volume = "26",
number = "8",
pages = "957-971",
doi = "10.1007/s00775-021-01905-4"
}

Isaković, A., Čolović, M. B., Ma, T., Ma, X., Jeremić, M., Gerić, M., Gajski, G., Misirlić-Denčić, S., Kortz, U.,& Krstić, D. Z.. (2021). Selected polyoxopalladates as promising and selective antitumor drug candidates. in JBIC Journal of Biological Inorganic Chemistry, 26(8), 957-971.
https://doi.org/10.1007/s00775-021-01905-4

Isaković A, Čolović MB, Ma T, Ma X, Jeremić M, Gerić M, Gajski G, Misirlić-Denčić S, Kortz U, Krstić DZ. Selected polyoxopalladates as promising and selective antitumor drug candidates. in JBIC Journal of Biological Inorganic Chemistry. 2021;26(8):957-971.
doi:10.1007/s00775-021-01905-4 .

Isaković, Anđelka, Čolović, Mirjana B., Ma, Tian, Ma, Xiang, Jeremić, Marija, Gerić, Marko, Gajski, Goran, Misirlić-Denčić, Sonja, Kortz, Ulrich, Krstić, Danijela Z., "Selected polyoxopalladates as promising and selective antitumor drug candidates" in JBIC Journal of Biological Inorganic Chemistry, 26, no. 8 (2021):957-971,
https://doi.org/10.1007/s00775-021-01905-4 . .

TY  - JOUR
AU  - Mirković, Marija D.
AU  - Radović, Magdalena
AU  - Stanković, Dragana
AU  - Milanović, Zorana
AU  - Janković, Drina
AU  - Matović, Milovan D.
AU  - Jeremić, Marija
AU  - Antić, Bratislav
AU  - Vranješ-Đurić, Sanja
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8156
AB  - Novel theranostic nanoplatform is expected to integrate imaging for guiding and monitoring of the tumor therapy with great therapeutic efficacy and fewer side effects. Here we describe the preparation of a multifunctional 99mTc–bisphosphonate–coated magnetic nanoparticles (MNPs) based on Fe3O4 and coated with two hydrophilic bisphosphonate ligands, i.e., methylene diphosphonate (MDP) and 1–hydroxyethane-1,1- diphosphonate (HEDP). The presence of the bisphosphonates on the MNPs surface, enabled their biocompatibility, colloidal stability and successful binding of the radionuclide. The morphology, size, structure, surface charge and magnetic properties of obtained bisphosphonate–coated Fe3O4 MNPs were characterized by transmission electron microscopy, X–ray powder diffraction, dynamic light scattering, laser Doppler electrophoresis, Fourier transform infrared spectroscopy and vibrating sample magnetometer. The specific power absorption values for Fe3O4–MDP and Fe3O4–HEDP were 113 W/g and 141 W/g, respectively, indicated their heating ability under applied magnetic field. Coated MNPs were radiolabeled with 99mTc using stannous chloride as the reducing agent in a reproducible high yield (95% for Fe3O4–MDP and 97% for Fe3O4–HEDP MNPs) and were remained stable in saline and human serum for 24 h. Ex vivo biodistribution studies presented significant liver and spleen uptake in healthy Wistar rats after intravenous administration at all examined time points due to the colloidal nature of both 99mTc–MNPs. Results of scintigraphy studies are in accordance with ex vivo biodistribution studies, demonstrating high in vivo stability of radiolabeled MNPs and therefore results of both methods were proved as accurate information on the biodistribution profile of investigated MNPs. Overall, in vitro and in vivo stability as well as heating ability, indicate that biocompatible radiolabeled bisphosphonate magnetic nanoparticles exhibit promising potential as a theranostic nanoagent. © 2019 Elsevier B.V.
T2  - Materials Science and Engineering: C
T1  - 99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent
VL  - 102
SP  - 124
EP  - 133
DO  - 10.1016/j.msec.2019.04.034
ER  - 

@article{
author = "Mirković, Marija D. and Radović, Magdalena and Stanković, Dragana and Milanović, Zorana and Janković, Drina and Matović, Milovan D. and Jeremić, Marija and Antić, Bratislav and Vranješ-Đurić, Sanja",
year = "2019",
abstract = "Novel theranostic nanoplatform is expected to integrate imaging for guiding and monitoring of the tumor therapy with great therapeutic efficacy and fewer side effects. Here we describe the preparation of a multifunctional 99mTc–bisphosphonate–coated magnetic nanoparticles (MNPs) based on Fe3O4 and coated with two hydrophilic bisphosphonate ligands, i.e., methylene diphosphonate (MDP) and 1–hydroxyethane-1,1- diphosphonate (HEDP). The presence of the bisphosphonates on the MNPs surface, enabled their biocompatibility, colloidal stability and successful binding of the radionuclide. The morphology, size, structure, surface charge and magnetic properties of obtained bisphosphonate–coated Fe3O4 MNPs were characterized by transmission electron microscopy, X–ray powder diffraction, dynamic light scattering, laser Doppler electrophoresis, Fourier transform infrared spectroscopy and vibrating sample magnetometer. The specific power absorption values for Fe3O4–MDP and Fe3O4–HEDP were 113 W/g and 141 W/g, respectively, indicated their heating ability under applied magnetic field. Coated MNPs were radiolabeled with 99mTc using stannous chloride as the reducing agent in a reproducible high yield (95% for Fe3O4–MDP and 97% for Fe3O4–HEDP MNPs) and were remained stable in saline and human serum for 24 h. Ex vivo biodistribution studies presented significant liver and spleen uptake in healthy Wistar rats after intravenous administration at all examined time points due to the colloidal nature of both 99mTc–MNPs. Results of scintigraphy studies are in accordance with ex vivo biodistribution studies, demonstrating high in vivo stability of radiolabeled MNPs and therefore results of both methods were proved as accurate information on the biodistribution profile of investigated MNPs. Overall, in vitro and in vivo stability as well as heating ability, indicate that biocompatible radiolabeled bisphosphonate magnetic nanoparticles exhibit promising potential as a theranostic nanoagent. © 2019 Elsevier B.V.",
journal = "Materials Science and Engineering: C",
title = "99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent",
volume = "102",
pages = "124-133",
doi = "10.1016/j.msec.2019.04.034"
}

Mirković, M. D., Radović, M., Stanković, D., Milanović, Z., Janković, D., Matović, M. D., Jeremić, M., Antić, B.,& Vranješ-Đurić, S.. (2019). 99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent. in Materials Science and Engineering: C, 102, 124-133.
https://doi.org/10.1016/j.msec.2019.04.034

Mirković MD, Radović M, Stanković D, Milanović Z, Janković D, Matović MD, Jeremić M, Antić B, Vranješ-Đurić S. 99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent. in Materials Science and Engineering: C. 2019;102:124-133.
doi:10.1016/j.msec.2019.04.034 .

Mirković, Marija D., Radović, Magdalena, Stanković, Dragana, Milanović, Zorana, Janković, Drina, Matović, Milovan D., Jeremić, Marija, Antić, Bratislav, Vranješ-Đurić, Sanja, "99mTc–bisphosphonate–coated magnetic nanoparticles as potential theranostic nanoagent" in Materials Science and Engineering: C, 102 (2019):124-133,
https://doi.org/10.1016/j.msec.2019.04.034 . .

TY  - CONF
AU  - Krstić, Dragana Ž.
AU  - Ilić, Radovan
AU  - Jovanović, Aleksandra
AU  - Nikezić, Dragoslav
AU  - Jeremić, Marija
AU  - Nikolić, Nebojša
AU  - Mihajlović, Jasmina
PY  - 2019
UR  - https://plus.sr.cobiss.net/opac7/bib/279687436
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8719
AB  - U radu je prikazano poređenje apsorbovanih doza u brahiterapijskim planovima i Monte Karlo simulacijama u brahiterapiji pacijentkinja sa karcinomom grlića materice. U Odeljenju za brahiterapiju u Kliničkom centru Kragujevac primenjuje se mikroSelektron za intrakavitarnu brahiterapiju u HDR režimu. Ovaj uređaj koristi minijaturni radioaktivni izvor 192Ir u obliku cilindra, aktivnih dimenzija 0,6 mm × 3,5 mm, i visoke početne aktivnosti od 370 GBq.Pre terapije, vrši se kompjutersko planiranje, koje predstavlja kompjutersku rekonstruk-ciju položaja vodiča izvora u pacijentu na osnovu dva radiografska snimka, i izodozno planiranje u odnosu na željene dozimetrijske tačke. Osnovni podaci planiranja su dnevna doza, koja iznosi 700 cGy i broj frakcija; dnevna doza se isporučuje se u tri frakcije jednom nedeljno. Monte Karlo simulacije su obavljene korišćenjem MCNP6 softvera verzije 2.0 kako bi se procenila raspodela doze u materici i kritičnim organima od rizika (bešika i debelo crevo). MCNP F6 tally (MeV/g) je izabran zbog lakog konvertovanja deponovane energije u apsorbovanu dozu. Za pripremu ulaznih datoteka koje simuliraju brahi-terapiju korišćeni su matematički ORNL i voksel fantomi. Upoređivanjem izmerenih i izračunatih vrednosti može se videti da su Monte Carlo tehnike moćno sredstvo za primenu u planiranju brahiterapije.
AB  - This paper presents the comparison of absorbed doses in brachytherapy plans and Monte Carlo simulation for brachytherapy treatment of a female patient with cervix carcinoma. At the Department of Brachytherapy at the Clinical Center Kragujevac, the microSelectron after loading deviceis used for intracavitary brachytherapy in the HDR regime. This device uses a miniature radioactive source 192Ir in the form of a cylinder, active dimensions of 0.6 mm × 3.5 mm, and a high initial activity of about 370 GBq. Before therapy, computer planning is performed, which represents a computer reconstruction of the position of the source guide in the patient based on two radiographic images, and isodose planning in relation to the desired dosimetry points. Essential planning data are the daily dose and number of fractions. In this case, the daily dose is 700 cGy and is delivered in three fractions once a week. This means that the duration of this brachytherapy treatment will be a total of three weeks. Monte Carlo simulations by using MCNP6 code version 2.0 were applied for brachytherapy treatment to estimate the dose distribution in uterus and several critical organs at risk (bladder and colon). The MCNP tally f6 (MeV/g) was chosen due to easy convert energy deposition toabsorbed dose. The computational ORNL and voxel phantoms were used to prepare input files which simulate brachytherapy.By comparing measured and calculated values, it can be seen that Monte Carlo techniques are a powerful tool for application in brachytherapy planning.
PB  - Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе
C3  - 30. симпозијум ДЗЗСЦГ : зборник радова
T1  - Monte Carlo dozimetrija u brahiterapiji kancera cerviksa
T1  - Monte Carlo dosimetry for brachytherapy of cervical cancer
SP  - 483
EP  - 488
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8719
ER  - 

@conference{
author = "Krstić, Dragana Ž. and Ilić, Radovan and Jovanović, Aleksandra and Nikezić, Dragoslav and Jeremić, Marija and Nikolić, Nebojša and Mihajlović, Jasmina",
year = "2019",
abstract = "U radu je prikazano poređenje apsorbovanih doza u brahiterapijskim planovima i Monte Karlo simulacijama u brahiterapiji pacijentkinja sa karcinomom grlića materice. U Odeljenju za brahiterapiju u Kliničkom centru Kragujevac primenjuje se mikroSelektron za intrakavitarnu brahiterapiju u HDR režimu. Ovaj uređaj koristi minijaturni radioaktivni izvor 192Ir u obliku cilindra, aktivnih dimenzija 0,6 mm × 3,5 mm, i visoke početne aktivnosti od 370 GBq.Pre terapije, vrši se kompjutersko planiranje, koje predstavlja kompjutersku rekonstruk-ciju položaja vodiča izvora u pacijentu na osnovu dva radiografska snimka, i izodozno planiranje u odnosu na željene dozimetrijske tačke. Osnovni podaci planiranja su dnevna doza, koja iznosi 700 cGy i broj frakcija; dnevna doza se isporučuje se u tri frakcije jednom nedeljno. Monte Karlo simulacije su obavljene korišćenjem MCNP6 softvera verzije 2.0 kako bi se procenila raspodela doze u materici i kritičnim organima od rizika (bešika i debelo crevo). MCNP F6 tally (MeV/g) je izabran zbog lakog konvertovanja deponovane energije u apsorbovanu dozu. Za pripremu ulaznih datoteka koje simuliraju brahi-terapiju korišćeni su matematički ORNL i voksel fantomi. Upoređivanjem izmerenih i izračunatih vrednosti može se videti da su Monte Carlo tehnike moćno sredstvo za primenu u planiranju brahiterapije., This paper presents the comparison of absorbed doses in brachytherapy plans and Monte Carlo simulation for brachytherapy treatment of a female patient with cervix carcinoma. At the Department of Brachytherapy at the Clinical Center Kragujevac, the microSelectron after loading deviceis used for intracavitary brachytherapy in the HDR regime. This device uses a miniature radioactive source 192Ir in the form of a cylinder, active dimensions of 0.6 mm × 3.5 mm, and a high initial activity of about 370 GBq. Before therapy, computer planning is performed, which represents a computer reconstruction of the position of the source guide in the patient based on two radiographic images, and isodose planning in relation to the desired dosimetry points. Essential planning data are the daily dose and number of fractions. In this case, the daily dose is 700 cGy and is delivered in three fractions once a week. This means that the duration of this brachytherapy treatment will be a total of three weeks. Monte Carlo simulations by using MCNP6 code version 2.0 were applied for brachytherapy treatment to estimate the dose distribution in uterus and several critical organs at risk (bladder and colon). The MCNP tally f6 (MeV/g) was chosen due to easy convert energy deposition toabsorbed dose. The computational ORNL and voxel phantoms were used to prepare input files which simulate brachytherapy.By comparing measured and calculated values, it can be seen that Monte Carlo techniques are a powerful tool for application in brachytherapy planning.",
publisher = "Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе",
journal = "30. симпозијум ДЗЗСЦГ : зборник радова",
title = "Monte Carlo dozimetrija u brahiterapiji kancera cerviksa, Monte Carlo dosimetry for brachytherapy of cervical cancer",
pages = "483-488",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8719"
}

Krstić, D. Ž., Ilić, R., Jovanović, A., Nikezić, D., Jeremić, M., Nikolić, N.,& Mihajlović, J.. (2019). Monte Carlo dozimetrija u brahiterapiji kancera cerviksa. in 30. симпозијум ДЗЗСЦГ : зборник радова
Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе., 483-488.
https://hdl.handle.net/21.15107/rcub_vinar_8719

Krstić DŽ, Ilić R, Jovanović A, Nikezić D, Jeremić M, Nikolić N, Mihajlović J. Monte Carlo dozimetrija u brahiterapiji kancera cerviksa. in 30. симпозијум ДЗЗСЦГ : зборник радова. 2019;:483-488.
https://hdl.handle.net/21.15107/rcub_vinar_8719 .

Krstić, Dragana Ž., Ilić, Radovan, Jovanović, Aleksandra, Nikezić, Dragoslav, Jeremić, Marija, Nikolić, Nebojša, Mihajlović, Jasmina, "Monte Carlo dozimetrija u brahiterapiji kancera cerviksa" in 30. симпозијум ДЗЗСЦГ : зборник радова (2019):483-488,
https://hdl.handle.net/21.15107/rcub_vinar_8719 .

TY  - CONF
AU  - Jeremić, Marija Ž.
AU  - Matović, Milovan D.
AU  - Krstić, Dragana Ž.
AU  - Nikezić, Dragoslav
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8294
UR  - https://plus.sr.cobiss.net/opac7/bib/245691404
UR  - http://dzz.org.rs/wp-content/uploads/2013/06/Zbornik_XXIX_Simpozijum_DZZ_SCG_Srebrno_jezero_2.pdf
AB  - У овом раду одређени су коефицијенти трансфера у биокинетичком моделу за
90Y-DOTATOC неуроендокриних тумора. Неуроендокрини тумори (NETs) су
малигни тумори који најчешће захватају органе гастроинтестиналног тракта и
панкреас (GEP-NETs), мада се могу јавити и на другим ткивима, као што су
плућа и ређе на дојкама, тимусу и урогениталном систему. Када су ови тумори
добро диферентовани, терапија избора је пептидна радионуклидна терапија
(PRRT), која се базира на аналозима соматостатина обележеним снажним бета
емитером, као што је 90Y, чији је максимални домет у меким ткивима 11,3 mm,
што омогућава да се са великом вероватноћом уништи велики део туморског
ткива и заустави прогресија малигне болести.
Циљ овог рада је да се на основу доступних метода мерења дистрибуције
90Y-DOTATOC у органима људског тела и на основу решења математичког
модела одреде трансфер коефицијенти за критичне органе, као и за тумор, а на
основу којих је касније могуће извршити прорачун апсорбованих доза у тим
органима и туморском ткиву.
AB  - Transfer coefficients in biokinetic model for 90Y-DOTATOC therapy of
neuroendocrinetumour (NETs) were determined in this work. These tumours are usually
treatted by DOTATOC therapy where some peptide was labeled with 90Y, which is a
strong beta emiter. The range of beta particles in soft tissues is less than 11.3 mm which
enables destroying of tumour cells with large probabiliy. The objective of this work was
to develop biokinetic model for 90Y-DOTATOC and to analytically solve obtained
equations. As a result of this model, the system with 10 equaitions and 12 unknown
constants was obtained. Two additional equations sjould be found: first one was
obtained from the normalisation of system and the second one from measurements.
PB  - Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе
C3  - 29. симпозијум ДЗЗСЦГ : зборник радова
T1  - Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију
T1  - Determination of transfer coefficients in biokinetic model for Y-90-DOTATOC therapy
SP  - 320
EP  - 327
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8294
ER  - 

@conference{
author = "Jeremić, Marija Ž. and Matović, Milovan D. and Krstić, Dragana Ž. and Nikezić, Dragoslav",
year = "2017",
abstract = "У овом раду одређени су коефицијенти трансфера у биокинетичком моделу за
90Y-DOTATOC неуроендокриних тумора. Неуроендокрини тумори (NETs) су
малигни тумори који најчешће захватају органе гастроинтестиналног тракта и
панкреас (GEP-NETs), мада се могу јавити и на другим ткивима, као што су
плућа и ређе на дојкама, тимусу и урогениталном систему. Када су ови тумори
добро диферентовани, терапија избора је пептидна радионуклидна терапија
(PRRT), која се базира на аналозима соматостатина обележеним снажним бета
емитером, као што је 90Y, чији је максимални домет у меким ткивима 11,3 mm,
што омогућава да се са великом вероватноћом уништи велики део туморског
ткива и заустави прогресија малигне болести.
Циљ овог рада је да се на основу доступних метода мерења дистрибуције
90Y-DOTATOC у органима људског тела и на основу решења математичког
модела одреде трансфер коефицијенти за критичне органе, као и за тумор, а на
основу којих је касније могуће извршити прорачун апсорбованих доза у тим
органима и туморском ткиву., Transfer coefficients in biokinetic model for 90Y-DOTATOC therapy of
neuroendocrinetumour (NETs) were determined in this work. These tumours are usually
treatted by DOTATOC therapy where some peptide was labeled with 90Y, which is a
strong beta emiter. The range of beta particles in soft tissues is less than 11.3 mm which
enables destroying of tumour cells with large probabiliy. The objective of this work was
to develop biokinetic model for 90Y-DOTATOC and to analytically solve obtained
equations. As a result of this model, the system with 10 equaitions and 12 unknown
constants was obtained. Two additional equations sjould be found: first one was
obtained from the normalisation of system and the second one from measurements.",
publisher = "Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе",
journal = "29. симпозијум ДЗЗСЦГ : зборник радова",
title = "Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију, Determination of transfer coefficients in biokinetic model for Y-90-DOTATOC therapy",
pages = "320-327",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8294"
}

Jeremić, M. Ž., Matović, M. D., Krstić, D. Ž.,& Nikezić, D.. (2017). Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију. in 29. симпозијум ДЗЗСЦГ : зборник радова
Београд : Институт за нуклеарне науке "Винча" : Друштво за заштиту од зрачења Србије и Црне Горе., 320-327.
https://hdl.handle.net/21.15107/rcub_vinar_8294

Jeremić MŽ, Matović MD, Krstić DŽ, Nikezić D. Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију. in 29. симпозијум ДЗЗСЦГ : зборник радова. 2017;:320-327.
https://hdl.handle.net/21.15107/rcub_vinar_8294 .

Jeremić, Marija Ž., Matović, Milovan D., Krstić, Dragana Ž., Nikezić, Dragoslav, "Одређивање трансфер коефицијената у биокинетичком моделу за Y-90-DOTATOC терапију" in 29. симпозијум ДЗЗСЦГ : зборник радова (2017):320-327,
https://hdl.handle.net/21.15107/rcub_vinar_8294 .